$6.50
0.76% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US14757U1097
Symbol
CASI
Sector
Industry

CASI Pharmaceuticals Inc Stock price

$6.50
+0.12 1.88% 1M
+0.61 10.36% 6M
-0.66 9.22% YTD
+4.33 199.91% 1Y
-9.70 59.88% 3Y
-28.80 81.59% 5Y
-10.40 61.54% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.05 0.76%
ISIN
US14757U1097
Symbol
CASI
Sector
Industry

Key metrics

Market capitalization $87.11m
Enterprise Value $92.85m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 4.16
P/S ratio (TTM) P/S ratio 3.90
P/B ratio (TTM) P/B ratio 7.89
Revenue growth (TTM) Revenue growth -42.24%
Revenue (TTM) Revenue $22.32m
EBIT (operating result TTM) EBIT $-34.22m
Cash position $12.73m
EPS (TTM) EPS $-2.02
P/E forward negative
P/S forward 4.40
EV/Sales forward 4.69
Short interest 1.58%
Show more

Is CASI Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

CASI Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast CASI Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast CASI Pharmaceuticals Inc:

Buy
100%

Financial data from CASI Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
22 22
-
100%
- Direct Costs 9.44 9.44
-
42%
13 13
-
58%
- Selling and Administrative Expenses 43 43
-
192%
- Research and Development Expense 4.24 4.24
-
19%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -34 -34
-
-153%
Net Profit -27 -27
-
-119%

In millions USD.

Don't miss a Thing! We will send you all news about CASI Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CASI Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
4 days ago
BEIJING , Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C.
Neutral
PRNewsWire
23 days ago
BEIJING , Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024. "The second quarter of 2024 was a ...
Positive
InvestorPlace
about one month ago
What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10.
More CASI Pharmaceuticals Inc News

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Head office United States
CEO Wei He
Employees 243
Founded 1991
Website www.casipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today